Spin-Offs
At C4C, we drive the creation of spin-offs as a bridge between research and real-world application. These companies emerge from our most advanced technological developments, with the goal of bringing innovative therapies to market, accelerating their impact on patients, and fostering a healthcare ecosystem grounded in science, technology, and entrepreneurship.
Avantiss
A biotechnology spin-off born from applied research at C4C. Its focus is on developing therapeutic solutions based on stem-cell–derived exosomes. These therapies aim to improve tissue regeneration and offer innovative treatments for high-complexity diseases. Avantiss represents the bridge between frontier science and real-world impact on people’s health. |
Regenero
The REGENERO consortium is a Chilean cell-therapy platform developing world-class biological products through research and development, translational medicine, and collaboration in shaping the local regulatory framework. |
EVast Bio
EVast Bio is a fast-growing, clinical-stage biotechnology company whose mission is to explore the vast potential of small extracellular vesicles (sEVs) as nanotherapeutics and targeted delivery systems. |
R-Matis
The first manufacturing center for advanced therapies in Chile, driven by C4C, the Regenero Consortium, FALP, and the Basal IMPACT Center. Its mission is to produce innovative cell therapies such as CAR-T, aimed at treating cancers including Acute Lymphoblastic Leukemia. |
Invest in C4C
Let’s talk about opportunities
We are open to building new relationships with investors who share our vision of transforming medicine from Latin America. Leave your details and we will contact you to schedule a meeting with our team. |
